SCHEMBL13156902

SCHEMBL13156902

CC1(C)C2CCC(CNC(=O)c3nn(-c4ccc(Cl)cc4Cl)c4c3CCc3sc(Cl)cc3-4)C1C2

nearest known ligand 0.75

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 14/20 0.75
▸ CNR1 P21554 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13218865 0.94 CNR2 (0.73) CNR2
SCHEMBL2774152 0.93 CNR2 (0.74) CNR2
SCHEMBL2773900 0.93 CNR2 (0.73) CNR2CNR1
SCHEMBL2772545 0.90 CNR2 (0.69) CNR2
SCHEMBL13175976 0.89 CNR2 (0.91) CNR2CNR1
SCHEMBL2774670 0.88 CNR2 (0.59) CNR2CNR1
SCHEMBL13218876 0.88 CNR2 (0.73) CNR2CNR1
SCHEMBL13218878 0.88 CNR2 (0.72) CNR2
SCHEMBL13218864 0.87 CNR2 (0.71) CNR2CNR1
SCHEMBL13176085 0.86 CNR2 (0.87) CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2230243-A1 Pharmaceutical compounds Neuroscienze Pharmaness S.C. A R.L. (IT) 2010-09-22 — — EP disclosed
US-20100215759-A1 PHARMACEUTICAL COMPOUNDS NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) 2010-08-26 — — US disclosed
US-20100215759-A1 PHARMACEUTICAL COMPOUNDS NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) 2010-08-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100215759-A1 PHARMACEUTICAL COMPOUNDS CNR2, CNR1, OPRK1 CNR2 1/4885CNR1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback